Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Diamond Blackfan Anemia Registry (DBAR) (DBAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00106015
Recruitment Status : Recruiting
First Posted : March 21, 2005
Last Update Posted : April 12, 2022
Diamond Blackfan Anemia Foundation, Inc.
Information provided by (Responsible Party):
Adrianna Vlachos, MD, Feinstein Institute for Medical Research

Brief Summary:
The purpose of this study is to maintain a comprehensive registry of patients with the rare inherited bone marrow failure syndrome Diamond Blackfan anemia (DBA).

Condition or disease
Anemia Blood Disease

Detailed Description:


Diamond Blackfan anemia (DBA) is a heterogeneous genetic disorder characterized by pure red cell aplasia, congenital anomalies, a predisposition to pancytopenia and myelodysplasia as well as hematopoietic and non-hematopoietic cancer. Anemia usually presents in infancy or early childhood and greater than 40% of patients have at least one congenital anomaly. The actuarial cancer risk is, as of yet, undetermined. One DBA gene has been cloned and the existence of at least two other DBA genes has been inferred by linkage analysis. Penetrance and expressivity of DBA genes are highly variable. "Affected" individuals within the same family may vary dramatically as to the degree of anemia, response to corticosteroids, the presence of congenital anomalies and the development of cancer. Despite improvements in understanding of this disorder there are significant deficiencies in knowledge that inhibit the exploitation of this syndrome to increase both specific and general knowledge of mechanisms of hematopoietic failure, birth defects and cancer predisposition. Furthermore this disease will, in the near future, provide a valuable platform to study complex gene interactions. There are less than 1000 individuals in the United States and Canada estimated to have DBA, representing at least 11 genotypes. Thus, no single center follows sufficient numbers of well-characterized patients for meaningful clinical and laboratory investigations. Furthermore, clinicians require an accurate knowledge of the clinical and laboratory presentation, mode of inheritance, treatment response, outcomes and prognosis to make important diagnostic treatment and reproductive decisions. A comprehensive registry that captures this information and characterizes patients accurately is therefore essential to advance our understanding of DBA, and in the process, knowledge regarding hematopoietic cell differentiation, birth defects and cancer predisposition. The registry will be an essential component of clinical and laboratory DBA related research and patient care.

The Diamond Blackfan Anemia Registry (DBAR) was established in 1992, and families were asked to participate if a member was affected by the disorder. From this, the Diamond Blackfan Anemia Foundation (DBAF) was established, largely as a cooperating entity for families to share information. The registry attempts to establish contact with all affected individuals at the time of diagnosis, avoiding the pitfalls of reporting bias inherent to the study of many diseases for which extraordinary events prompt referral to specialized centers. The registry is already capturing a high percentage of the estimated number of new cases per year, and has facilitated genetic studies to define the gene(s) responsible for the disorder. Thus, the registry has an established track record based on funding from non-NIH sources.

The study is in response to RFA HL-04-008 on Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow Failure Syndromes.


The objective of this study is to expand and update the DBAR in order to: 1) facilitate investigations into the epidemiology and biology of Diamond Blackfan anemia; 2) provide an accurate phenotype of DBA patients to facilitate genotype- phenotype correlations; 3) provide access of well characterized patients to treatment protocols; 4) provide patients to access to research studies; 5) provide patients with results of research studies; 6) serve as a resource to patients and their doctors to guide diagnostic, therapeutic, and reproductive decisions.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 900 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diamond Blackfan Anemia Registry (DBAR)
Actual Study Start Date : September 2004
Estimated Primary Completion Date : April 2026
Estimated Study Completion Date : April 2026

Primary Outcome Measures :
  1. Understanding the epidemiology and biology of Diamond Blackfan anemia [ Time Frame: yearly ]

Biospecimen Retention:   Samples With DNA
DNA from peripheral blood and/or bone marrow

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
All subjects diagnosed with Diamond Blackfan anemia

Inclusion Criteria:

  • Patients must meet the diagnostic criteria for DBA which include the following:

    1. Normochromic, usually macrocytic and occasionally normocytic anemia developing early in childhood
    2. Reticulocytopenia
    3. Normocellular bone marrow with a selective deficiency of red cell precursors
    4. Normal or slightly decreased leukocyte count
    5. Normal or often increased platelet count
    6. Or, a confirmed mutation in one of the identified DBA genes

Exclusion Criteria:

  • Any subject identified as having another bone marrow failure syndrome (eg. Fanconi anemia, dyskeratosis congenita, Shwachman Diamond syndrome, etc.) will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00106015

Layout table for location contacts
Contact: Eva Atsidaftos, MA 718-470-5523

Layout table for location information
United States, New York
Cohen Children's Medical Center of NY Recruiting
New Hyde Park, New York, United States, 11040
Contact: Eva Atsidaftos, MA    518-562-1504   
Principal Investigator: Jeffey M Lipton, MD, PhD         
Sub-Investigator: Adrianna Vlachos, MD         
Sponsors and Collaborators
Feinstein Institute for Medical Research
Diamond Blackfan Anemia Foundation, Inc.
Layout table for investigator information
Principal Investigator: Adrianna Vlachos, MD Cohen Children's Medical Center of NY/Feinstein Institutute for Medical Research
Study Chair: Jeffrey M Lipton, MD, PhD Cohen Children's Medical Center of NY/Feinstein Institute for Medical Research
Additional Information:
Publications of Results:

Other Publications:

Layout table for additonal information
Responsible Party: Adrianna Vlachos, MD, Director, Feinstein Institute for Medical Research Identifier: NCT00106015    
Other Study ID Numbers: 1288
First Posted: March 21, 2005    Key Record Dates
Last Update Posted: April 12, 2022
Last Verified: April 2022
Keywords provided by Adrianna Vlachos, MD, Feinstein Institute for Medical Research:
inherited pure red cell aplasia
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Diseases
Anemia, Diamond-Blackfan
Anemia, Hypoplastic, Congenital
Anemia, Aplastic
Red-Cell Aplasia, Pure
Congenital Bone Marrow Failure Syndromes
Bone Marrow Failure Disorders
Bone Marrow Diseases
Genetic Diseases, Inborn